TRC: Thiazolidinediones

Thiazolidinediones

Thiazolidinediones are a new group of drugs that improve insulin sensitivity. The precise mechanism of action is not known. Thiazolidinediones bind to peroxisome proliferator-activated receptors in the nucleus (PPARs), specifically PPARγ. In that way, thiazolidinediones alter transcription of certain genes. They are most effective in adipose tissue, muscle tissue and the liver.
Rosiglitazon

style="color: #000040; font-family: Verdana, Arial; font-size: medium; background-color: #e4eaff;"> and pioglitazon belong to this group of drugs.
When metformin or sulphonylderivatives are not effective, addition of thiazolidinediones to these drugs might obtain better effectivity.

I. Thiazolidinediones modulate gene expression. II. Thiazolidinediones can be used during pregnancy.

Extra info: There is not enough information available about the use of thiazolidinediones during pregnancy and lactation. However, during animal testing, thiazolidinediones turned out to be harmful. Therefore pregnant and lactating women must not use these agents.

I is true, II is false

I is true, II is true

I is false, II is false

I is false, II is true

Thiazolidinediones are useful for the treatment of

Extra info: Thiazolidinediones stimulate the action of insulin and thus they are only effective in type 2 diabetes mellitus.

diabetes mellitus type 1

diabetes mellitus type 2

both diabetes mellitus type 1 and 2

hypoglycemia

Thiazolidinediones

Thiazolidinediones

You may also like